mteb/BIRCO-Arguana-Test huggingface dataset:
disease health general house would allow production generic drugs When generic drugs are legalized firms and individuals no longer feel the incentive to misallocate resources to the race to patent new drugs and to monitor existing patents, or to spend resources stealing from one another  Patent regimes cause firms to inefficiently allocate resources. One such inefficiency arises from the duplication of effort by firms seeking to develop the same or very similar drugs, though only the first to do so may profit from it due to the winner-takes-all patent system. This leads to brutal races and excessive expenditure of resources to be first over the line and to monopolize the production, at least for a time. These races can thus lead to efforts by firms to steal research from one another, thus resulting in further wastes of resources in engaging and attempting to prevent corporate espionage. Another serious inefficiency arises in the production of similar products to existing ones, seeking to get around existing patents. Such has been the case for years in the pharmaceutical industry, which has succeeded, for example, in curing erectile dysfunction dozens of times. An overemphasis on such spinning off of similar products is the result of patent-generated inefficiency 1. The inefficiency does not end with production, however, as firms likewise devote great amounts of resources and effort to the development of non-duplicable products, in monitoring for infringement, and in prosecuting offenders, all of which generates huge costs and little or no return 2. Furthermore, the deterrent effect to patent piracy generated by all the efforts of the state and firms has proven generally minimal. Clearly, in the absence of patent protection for pharmaceuticals, markets and firms will behave more efficiently. This is shown by the introduction of generic antiretroviral drugs for treating AIDS where the introduction of generic drugs forced the price of the branded drugs down from $10439 to $931 in September/October 2000 3.  1 Gabb, Sean. 2005. "Market Failure and the Pharmaceutical Industry: A Proposal for Reform". National Health Federation. Available: 2 World Intellectual Property Organization. 2011. "Emerging Issues in Intellectual Property". Available: 3 Avert.org, "AIDS, Drug Prices and Generic Drugs",
disease healthcare international africa censorship ip house would produce high Some countries, such as India and Thailand, have specialised in producing generic drugs. These states provide the majority of generic drugs to Africa. This removes the burden of other countries to supply Africa with their own drugs whilst potentially damaging their own research companies. India has managed to create a very profitable industry based around cheap generic drugs which it mainly exports to the African continent [1] , decreasing the necessity of other states to contribute vast resources.  Providing generics to Africa will not damage development by the big pharmaceutical companies as at the moment these countries cannot afford the drugs so are not a market. The drugs are researched on the assumption that they will be sold in the developed world. What matters therefore is to ensure that generics for Africa don’t get sold back to the developed world undercutting patented drugs.  [1] Kumar,S. ‘India, Africa’s Pharma’
disease healthcare international africa censorship ip house would produce high Most vital drugs are already generic  Many drugs which are used in the treatment of HIV, malaria and cancer are already generic drugs which are produced in their millions [1] . This removes the necessity to provide further high quality generic drugs as there is already an easily accessible source of pharmaceuticals. Effective treatments for Malaria, in conjunction with prevention methods, have resulted in a 33% decrease in African deaths from the disease since 2000 [2] . The drugs responsible for this have been readily available to Africa, demonstrating a lack of any further need to produce pharmaceuticals for the continent.  [1] Taylor,D. ‘Generic-drug “solution” for Africa not needed’  [2] World Health Organisation ’10 facts on malaria’, March 2013
disease healthcare international africa censorship ip house would produce high Dominance of generic drugs will reduce reinvestment and innovation in donating countries  The production of high quality generic drugs endangers pharmaceutical progress. In order to export high quality generic drugs, some countries have suggested allowing generic drug manufacturers access to patented drugs. In Canada, amendments to Canada’s Access to Medicine Regime (CAMR) would have forced pharmaceutical research companies to give up their patents [1] . This is problematic however as research based companies invest a large proportion of their profits back in to the industry. The requirements proposed for some Western countries for obligatory quantities of generic drugs to be given to Africa have been accused to removing any incentive to invest in research to combat disease [2] .  [1] Taylor,D. ‘Generic-drug “solution” for Africa not needed’  [2] ibid
disease health general house would allow production generic drugs The product of a firm's intellectual endeavor is the property of that firm, and it deserves to profit from it  When a firm directs individuals to mix their labor with its capital or other resources, part of that firm's identity inheres in the product that arises from the effort. This is the origin of, and fundamental philosophical justification for, property rights. Property rights are an unquestioned mainstay of life in all developed countries, and are an essential prerequisite for stable markets to develop and function1. The law protects patent rights in much the same way as more conventional physical property, as well it should. Individuals and firms generating ideas and using their effort to produce an intangible good, such as a new drug formula, have a property right on those ideas and the products that arise from them. It is the effort to produce a real good, albeit an intangible one, that marks the difference between an idea in someone's head that he does not act up, and intellectual property that can be protected by a patent. Developing a new drug is a very intensive endeavor, taking time, energy, and usually a considerable amount of financial investment2. The cost of developing a new drug varies widely, from a low of $800 million to nearly $2 billion per drug and is rising3. People and firms deserve as a matter of principle to benefit from the products of the effort of creation. For this reason, stealing intellectual property, which developing generic drugs is, is the same as stealing an actual physical product. Each is a real thing, even if one can be touched while the other is intangible in a physical sense. As a matter of principle, property rights can be assigned to intangible assets like drug formulae, and in practice they are a necessity to many firms' financial survival.  1Fitzgerald, Brian and Anne Fitzgerald. 2004. Intellectual Property: In Principle. Melbourne: Lawbook Company. 2 Congressional Budget Office. 2006. Research and Development in the Pharmaceutical Industry". The Congress of the United States. Available: 3 Masia, Neal, 2008, "The Cost of Developing a New Drug", Focus on Intellectual Property Rights, America.gov, Available:
disease healthcare international africa censorship ip house would produce high Easily affordable drugs will mean greater access  Generic drugs are much cheaper to produce, which is ideal for Africa’s struggling population. While there has been significant gross domestic product (GDP) growth in Africa, the actual distribution of wealth is relatively unequal. According to Afrobarometer, 53% of Africans still feel that their economic condition is poor [1] . This restricts their ability to purchase high cost drugs. Generic medication would reduce the price of these drugs, making them affordable to the average citizen. The patented drug Glivec, used for cancer treatment, costs £48.62 for 400 mg in South Africa while its generic equivalent (produced in India) costs £4.82 [2] . Increased access will result in higher levels of treatment, which in turn will reduce death rates from preventable diseases in Africa.  [1] Hofmeyr, Jan, ‘Africa Rising? Popular Dissatisfaction with Economic Management Despite a Decade of Growth’  [2] Op Cit
disease healthcare international africa censorship ip house would produce high Greater access of generic drugs can increase the chances of overexposure and misuse. This has a detrimental effect on fighting diseases. Greater access will lead to higher use rates which, in turn increases the chances of the disease developing an immunity to the drug [1] , as is already happening to antibiotics resulting in at least 23,000 deaths in the United States. [2] This immunity requires new pharmaceuticals to counteract the disease which can take years to produce. It is therefore, disadvantageous to produce high quality generic drugs for Africa.  [1] Mercurio,B. ‘Resolving the Public Health Crisis in the Developing World: Problems and Barriers of Access to Essential Medicines’ pg.2  [2] National Center for Immunizations and Respiratory Diseases, ‘Antibiotics Aren’t Always the Answer’, Centers for Disease Control and Prevention, 16 December 2013,
disease health general house would allow production generic drugs Patent rights allow firms to more readily release their products and methods into the public domain, particularly through licensing  Without patent protection, innovative and enterprising firms lacking the capacity to market successfully or efficiently produce new drugs might develop new drugs and never release them, since it would simply result in others profiting from their efforts. After all, no one likes to see others profit by their hard work, and leaving them nothing; such is tantamount to slavery. Patent protection encourages the release of new ideas and products to the public, which serves to benefit society generally1. The main mechanism for this is the system of licensing, by which firs can retain their right of ownership over a drug while essentially renting the ability to produce it to firms with productive capacities that would better capitalize on the new product. Furthermore, the disclosure of ideas to the public allows firms to try to make the product better by "inventing around" the initial design, or by exploiting it once the term of the patent expires2. If the drug formula never enters the public, it might never do so, leaving society bereft of a potentially valuable asset.  1 Rockwell, Llewellyn. 2011. "The Google Pharm Case". Mises Daily. Available: 2 Business Line. 2007. "Patents Grant Freedom to Invent Around". Hindu Business Line. Available:
disease healthcare international africa censorship ip house would produce high The use of generic drugs can sometimes fail to bring about a reduced price. For the cost of drugs to decrease, there must be competition within the industry to drive prices down. The switch from patented to generic drugs in Ireland failed to bring about any significant saving for this reason [1] . African countries must therefore ensure competition in order for generic drugs to become truly affordable which could be problematic due to continued protectionism in some states.  [1] Hogan,L. ‘Switch to generic drugs fails to bring expected savings for HSE’
disease health general house would allow production generic drugs Allowing the production of generic drugs will only increase production of drugs currently on the market. Without the profit incentive that patents provide, pharmaceutical companies will not invest in the expensive process of developing new drugs in the first place. It is a necessary trade-off, as patents are essential to incentivize innovation. Furthermore, many states have mandatory licensing laws in states requiring companies to license the rights to the production of drugs so as not to precipitate shortages.
disease healthcare international africa censorship ip house would produce high Unfair to apply same patent laws universally  It is unrealistic to expect poorer countries, such as those in Africa, to pay the same price as the developed world’s markets. Current patent laws for many countries dictate that prices for buying patented drugs should be universally the same. This makes it extremely difficult for African countries to purchase pharmaceuticals set at the market price of developed countries. In the US there are nine patented drugs which cost in excess of $200,000 [1] . To expect developing African states to afford this price is unfair and reinforces the exploitative relationship between the developed and developing world. Generic drugs escape this problem due to their universally low prices.  [1] Herper,M. ‘The World’s Most Expensive Drugs’
disease healthcare international africa censorship ip house would produce high Cheaper drugs aren’t trusted by consumers  The differences in price between generic and patented drugs can be disconcerting to those wishing to buy pharmaceuticals. As with other product, logic generally follows the rule that the more expensive option is the most effective. There are reports from the USA of generic drugs causing suicidal tendencies [1] . These factors, combined with the lower levels of screening for drugs in Africa, mean that cheaper drugs are generally distrusted [2] .  [1] Childs,D. ‘Generic Drugs: Dangerous Differences?’  [2] Mercurio,B. ‘Resolving the Public Health Crisis in the Developing World: Problems and Barriers of Access to Essential Medicines’
disease healthcare international africa censorship ip house would produce high Reduce the prominence of bad and fake drugs  The increased availability of high quality generic drugs will reduce the numbers of bad and fake pharmaceuticals on the markets. The cost of patented drugs has forced many to search for other options. This is exploited by the billion dollar global counterfeit drug trade [1] . Fake drugs are the cause of around 100,000 deaths in Africa every year. Bad drugs, which are substandard, have also found their way in to Africa; one in six tuberculosis pills have been found to be of a poor quality [2] . The widespread introduction of low cost, high quality drugs will hopefully ensure that consumers do not turn to sellers in market places.  [1] Sambira,J. ‘Counterfeit drugs raise Africa’s temperature’  [2] Ibid
disease health general house would allow production generic drugs Research and development will continue, irrespective of intellectual property rights. The desire of firms to stay ahead of the competition will drive them to invest in research regardless. That their profits will be diminished by the removal of intellectual property rights is only natural and due to the fact that they will no longer have monopoly control over their intangible assets, and will thus not be able to engage in the rent-seeking behavior inherent in monopoly control of products. The costs of commercialization, which include building factories, developing markets, etc., are often much higher than the costs of the initial conception of an idea1 these are areas where competition will force down costs. Furthermore, there will always be demand for a brand name over a generic product. In this way the initial producer can still profit more than generic producers, if not at monopolistic levels.  1Markey, Justice Howard. 1975. Special Problems in Patent Cases, 66 F.R.D. 529.
disease healthcare international africa censorship ip house would produce high Savings can be used in other sections of medical care  The decreased cost of pharmaceuticals allows African states to focus on other aspects of medical schemes. Pharmaceuticals are not the only aspect in treatment, there needs to be sufficient staff, medical equipment and infrastructure [1] . These requirements cost money, which the savings made on pharmaceuticals provide. In Europe, 50% of dispensed medicines are generic yet they cost only 18% of pharmaceutical expenditure, with a similar model predicted for South Africa. This allows the state to focus on other aspects of medical schemes [2] .  [1] Ibid  [2] Health24, ‘South Africans embrace generic meds’
disease healthcare international africa censorship ip house would produce high Medically there is no difference between generic and patented drugs. They are both identical, with the exception of aesthetic differences in some US drugs to avoid copyright infringement. Generic drugs cost less because they do not have to invest in R&amp;D [1] . They focus on efficient methods of production and ensure that their product can be sold at a competitively low price. The lack of a need for R&amp;D is therefore more prominent than quality in the pricing of generic drugs.  [1] Stoppler,M. ‘Generic Drugs, Are They as Good as Brand Names?’
disease healthcare international africa censorship ip house would produce high Pharmaceutical companies investing in R&amp;D deserve to make a return on their investments. Research and development can take a long time and will cost significant sums of money. The cost of creating many new drugs was estimated to be as high as $5 billion in 2013 [1] . There is also a risk that the drug may fail during the various phases of production, which makes the $5 billion price-tag even more daunting. It is therefore necessary for these companies to continue to make a profit, which they do through patenting. If they allow drugs to immediately become generic or subsidise them to some of the biggest markets for some diseases then they shall make a significant financial loss.  [1] Herper,M. ‘The Cost of Creating a New Drug Now $5 Billion, Pushing Big Pharma to Change’
disease health general house would allow production generic drugs The costs associated with the current patent regime are necessary to the maintenance of innovation. It may be costly, and technically inefficient to police property rights, but that does not make them less of a right. If firms feel they can benefit from fighting infringers of their patent rights, it is their right to do so. The state likewise, has an obligation to protect the rights, physical and intangible, of its citizens and cannot give up on them simply because they prove difficult and costly to enforce.
disease health general house would allow production generic drugs There is nothing unjust about the patent system. It protects everyone equally. The nature of democracy is such that people are allowed to express their opinions and to organize to further certain aims. Drug companies have a particular interest in protecting their patent rights so it is only natural that they should involve themselves in the process of how those patents should be treated legally. They are not miscreants, but rather are participants in a system that is designed to be as fair as possible for everyone.
disease health general house would allow production generic drugs You cannot own an idea, and thus cannot hold patents, especially to vital drugs  An individual's idea, so long as it rests solely in his mind or is kept safely hidden, belongs to him. When he disseminates it to everyone and makes it public, it becomes part of the public domain, and belongs to anyone who can use it. If individuals or firms want to keep something a secret, like a production method, then they should keep it to themselves and be careful with how they disseminate their product. One should not, however, expect some sort of ownership to inhere in an idea one has, since no such ownership right exists1. No one can own an idea. Thus recognizing something like a property right over something like a drug formula is contrary to reason, since doing so gives monopoly power to individuals who may not make efficient or equitable use of their asset. Physical property is a tangible asset, and thus can be protected by tangible safeguards. Ideas do not share this right to protection, because an idea, once spoken, enters the public domain and belongs to everyone. This should apply all the more with vital drugs that are fundamentally for the public good by improving health.  1Fitzgerald, Brian and Anne Fitzgerald. 2004. Intellectual Property: In Principle. Melbourne: Lawbook Company.
aw society family house would allow patenting genes Patenting inhibits research and therapeutics  The prevailing belief is that this is an area of such great importance and potential benefit to mankind, as such there should be no, self-interested impediment to genome research. The only barriers should be those of conscience.  The Human Genome Project is one of the government funded projects that makes all its research freely and publicly available. They are not driven by profit and offer information on their discoveries for free enabling others to build upon their findings.  The problem with patents is that companies claim ownership without regard towards moral issues. It is purely in the pursuit of their profits that they decide not to allow others to build on their findings and make the process of discovering treatments far more difficult. An example of this is the Myriad company which, whilst holding patents on BRCA 1 &amp; 2, genes connected with breast cancer, prevented the University of Pennsylvania from using a test for these genes which was substantially cheaper than the company’s own screening procedure. 1  Instead of protecting their research investment, companies should have a moral duty to facilitate in any way they can to the development of cheap, available treatments and screenings for diseases which are so dangerous to so many people.  1. Spektor, Michelle, "Genes Are Still Patentable, Federal Appeals Court Rules", Science Progress, 17 August 2011,
th health general global law crime policing law general punishment house would Legalising coca production would undemine the wider war on the drugs economy  The UN International Narcotics Control Board (INCB) said in 2011 that exceptions for Bolivia would undermine international narcotics control efforts: “[Allowing coca] would undermine the integrity of the global drug control system, undoing the good work of governments over many years.” [1] A US official said in January of 2011: “there is evidence to suggest that a substantial percentage” of the increased coca production in Bolivia over the past several years, registered in U.N. surveys, “has indeed gone into the network and the marketplace for cocaine.” [2] These examples thus show that legalizing coca cultivation would undermine the wider war on drugs, because it shifts the policy away from one of eradicating crops which could be turned into narcotics and instead turns towards making them acceptable on the global market. It encourages countries to take eradication efforts less seriously, and seemingly undermines the commitment of the international community to the war on drugs, once it gives in on this narcotic. This will make not just cocaine but many other drugs more widely available, leading to even more ruined lives through drug abuse.  [1] M&amp;C News. “Bolivia undermines global anti-drug efforts, UN warns”. M&amp;C News. Jul 5, 2011.   [2] Associated Press. “U.S. to fight Bolivia on allowing coca-leaf chewing”. The Portland Press Herald. January 19 2011.
sex sexuality international africa religion church morality house believes Radical changes risk stability of the Catholic Church. As outlined in the main proposition case, rather than making the Catholic Church seem as if it can move with the times, suddenly changing its stance on barrier contraception would make the Church seem weak and would lose a lot of its support. Since their stance on barrier contraception is something that the Catholic Church has stood by for a huge number of years suddenly moving on it would throw their conviction on everything into question and would have a severe negative effect on the stability of the Church.